let's take a closer look with brent saunders. he's the president and ceo of allergan. brent, welcome back to "mad money." >> thank you. >> we got to get right to it. on the conference call this why are you overpaying for these things? and i need you to tell our viewers because your stock's been getting hit when you make these acquisitions. >> i think criticism is always helpful. we love the feedback. i love to get the feedback from shareholders, but i don't think we overpaid. i think we paid a competitive price for tobira. >> competitive with who? >> i think we got a home run on vitae. >> were there really other companies bidding for this thing and you had to -- there were? >> there were other companies and when you see the regulatory filings come out from tobira, i think the picture will be clearer and you'll be able to understand it better. but put that aside. $595 million for a potentially phase three ready asset in one of the largest unmet medical